Duchenne Muscular Dystrophy Gene Therapy

Duchenne muscular dystrophy (DMD) is one of those diagnoses that hits like a dropped dumbbell: loud, heavy, and
immediately life-changing. It’s a genetic condition that causes progressive muscle damage, and for decades the best
medicine could offer was a mix of “slow it down,” “support the heart and lungs,” and “let’s keep you moving as long
as possible.”

Then gene therapy showed uplike the bold friend who says, “What if we fixed the problem closer to the source?”
Spoiler: we’re not at “fixed” yet. But we are in a new era where a single infusion can deliver a working
genetic blueprint that helps muscle cells make a version of dystrophin (the missing protein in Duchenne).
That’s huge. It’s also complicated, expensive, andbecause biology enjoys plot twistssometimes risky.

This article breaks down Duchenne muscular dystrophy gene therapy in plain American English: how it works, what’s
actually approved in the U.S., what the safety conversations look like today, and what families often experience in
real life (yes, including the “why does every appointment require three snacks and a backup charger?” part).

Duchenne in plain English: what’s going wrong?

Duchenne is caused by mutations in the DMD gene, which normally provides instructions for making
dystrophina key structural protein that helps protect muscle cells during contraction. Without
enough functional dystrophin, muscle fibers become fragile, get damaged repeatedly, and are gradually replaced by
fat and scar tissue. Duchenne primarily affects boys and typically starts showing up in early childhood with
delayed motor milestones, trouble running or climbing, and a characteristic “Gowers’ sign” (using hands to push off
the thighs to stand). Over time, it can affect heart and breathing muscles too.

In terms of frequency, Duchenne and Becker muscular dystrophies together affect roughly 1 in 3,500 to 5,000 newborn
males worldwide, and hundreds of boys in the U.S. are born with these conditions each year. The reason this matters:
it’s rare, but not “unicorn rare.” Most large children’s hospitals and neuromuscular clinics have seen itand
the Duchenne community has built serious expertise and advocacy as a result.

Why gene therapy is a big deal (and why it’s hard)

The dream of gene therapy for Duchenne is straightforward: deliver genetic instructions to muscle cells so they can
produce a dystrophin-like protein and stabilize muscle tissue. The “hard” part is the engineering:

• The dystrophin gene is enormous. It doesn’t fit into the most commonly used delivery vehicle
  for systemic gene therapy.
• Muscle is everywhere. Skeletal muscles plus the heart plus the diaphragm means the therapy has
  to reach a lot of tissuenot just one organ.
• Your immune system has opinions. The body can react to the viral vector used for delivery, and
  those reactions can be mild… or serious.
• Durability is still being proven. Even when the body produces micro-dystrophin, the long-term
  functional impact and how long benefits last are areas of active study.

So gene therapy in Duchenne is best understood as a powerful toolone that may slow progression and preserve
function in some patientsrather than a guaranteed “one-and-done cure.”

How Duchenne gene therapy works: AAV delivery + “micro-dystrophin”

Most leading Duchenne gene therapies use an adeno-associated virus (AAV) vector. Think of AAV as a
delivery truck that drops genetic instructions into cells. It’s engineered so it can’t replicate and doesn’t cause
a viral illness. The payload is a gene that encodes a smaller version of dystrophin called micro-dystrophin.

Why “micro” and not the full dystrophin gene?

Because the full dystrophin gene is too large to fit into an AAV vector. So researchers design a “travel-size”
dystrophinsmall enough to ship, but built to keep the most important functional domains. Is it identical to natural
dystrophin? No. Is it potentially helpful? That’s the goal: a shorter but functional protein that helps protect
muscle cells from damage.

What happens during infusion day (high level)

AAV-based Duchenne gene therapy is typically delivered as a single intravenous infusion at a specialized center.
Patients are usually started on a corticosteroid regimen around treatment to reduce immune reactions and protect
against complications. After infusion, the medical team closely monitors labs and symptoms for weeks to months,
because certain serious side effects (especially involving the liver) can occur after treatment.

This is why gene therapy isn’t “take this once and never see your doctor again.” It’s more like, “take this once
and become close friends with your lab draw station for a while.”

The U.S. approved gene therapy option: ELEVIDYS

In the United States, the firstand currently onlyapproved gene therapy for Duchenne muscular dystrophy is
ELEVIDYS (delandistrogene moxeparvovec-rokl), an AAVrh74 vector-based gene therapy designed to
deliver the micro-dystrophin gene.

Approval timeline: 2023 → 2024 → 2025 (and why dates matter)

The timeline matters because eligibility and labeling have changed as safety data evolved:

• June 22, 2023: The FDA granted accelerated approval for ELEVIDYS for ambulatory pediatric
  patients ages 4 through 5 with Duchenne, based on micro-dystrophin expression as a surrogate endpoint.
• June 20, 2024: The FDA expanded approval to ambulatory and non-ambulatory individuals 4 years
  of age and older with a confirmed DMD mutation (with different approval pathways for different subgroups).
• November 14, 2025: Following reports of fatal acute liver failure in non-ambulatory
  patients, the FDA approved new labeling that added a Boxed Warning and limited ELEVIDYS to
  ambulatory patients 4 years and older, removing the non-ambulatory indication.

Bottom line: if you read an older article online, it may describe eligibility that is no longer current. Always
confirm the latest label and your clinic’s criteria before making plans.

Who may be eligibleand who isn’t

As of the revised U.S. labeling (late 2025), ELEVIDYS is indicated for ambulatory patients
4 years of age and older with Duchenne muscular dystrophy and a confirmed mutation in the DMD gene.
But there are important caveats.

• Contraindication: ELEVIDYS should not be used in patients with deletions involving
  DMD exons 8 and/or 9.
• Antibodies matter: Patients are selected based on anti-AAVrh74 antibody testing. Elevated
  antibody levels can make treatment unsafe or ineffective.
• Limitations of use: It’s not recommended in patients with preexisting liver impairment, recent
  vaccination, or active/recent infections because of immunogenicity and safety concerns.
• Re-dosing is not done: The prescribing information states not to re-administer ELEVIDYS.

Eligibility can feel like a frustrating checklist, but it exists for a reason: gene therapy is powerful, and the
risk profile differs from standard medications.

What benefits are realistic?

With Duchenne gene therapy, it’s best to frame expectations around preserving function rather than
“reversing Duchenne.” In clinical development and post-approval experience, the hope is that micro-dystrophin
expression can slow muscle damage and help maintain strength and mobility longer than would otherwise occur.

However, Duchenne progresses differently from person to person. Age at treatment, baseline function, mutation type,
steroid regimen, and immune response can all influence outcomes. Even in the best-case scenario, patients typically
still need standard Duchenne care (cardiac, pulmonary, rehab, nutrition, bone health, and psychosocial support).

Safety: the “read this before you assume it’s just an IV and a sticker” section

Gene therapy comes with a safety conversation that is more intense than most families are used tobecause it can
involve serious risks, including rare but life-threatening complications.

Liver risks and the Boxed Warning

In November 2025, the FDA approved a new Boxed Warning for ELEVIDYS describing the risk of
acute serious liver injury and acute liver failure, including fatal outcomes. The action followed
reports of fatal acute liver failure in non-ambulatory patients, and the FDA also removed the non-ambulatory
indication. Liver complications typically showed up within the first couple of months post-infusion in the reported
fatal cases.

Monitoring isn’t optional. The revised labeling recommends:

• Weekly liver function tests for at least three months after treatment (and longer if needed).
• Patients should remain near an appropriate medical facility for at least two months
  after infusion, as determined by the healthcare provider.
• Prompt specialist consultation (for example, gastroenterology/hepatology) if serious liver injury is suspected.

Translation: gene therapy is not a “get infused on Friday and fly out for a theme park weekend on Saturday” kind of
event. It’s closer to “plan for close follow-up and a calendar that suddenly becomes 70% lab appointments.”

Infections, myocarditis, and infusion reactions

The updated label highlights that corticosteroid therapy used around infusion can suppress immune function, raising
the risk of serious infections. Cardiac monitoring is also emphasized: weekly troponin-I testing
for about one month after treatment is advised to monitor for cardiac injury.

Infusion-related reactions can occur as well (sometimes immediately, sometimes afterward). Clinics are prepared for
this, which is one reason treatment occurs at specialized centers with protocols and observation periods.

Gene therapy doesn’t replace Duchenne careit joins the team

Even with gene therapy, standard Duchenne care remains essential. Expert care guidelines emphasize ongoing
management across multiple systems, including:

• Corticosteroids (when appropriate) to slow functional decline
• Cardiac care (monitoring and early treatment for cardiomyopathy)
• Pulmonary care (lung function monitoring and respiratory support when needed)
• Physical therapy and mobility support (stretching, orthotics, assistive devices)
• Bone health and fracture prevention, especially with steroid use

If you’ve ever felt like Duchenne care involves “a small committee of specialists,” you’re not imagining it. But
that team approach is also why outcomes have improved over timepeople with Duchenne are living longer today than in
previous generations because supportive care is better and more systematic.

Cost and access: the practical reality

Gene therapy is not just a medical decision; it’s also a logistics-and-insurance marathon. One-time gene therapies
can be priced in the millions, and access often depends on payer policies, prior authorization, center-of-excellence
requirements, and documentation of eligibility criteria.

Many families report that the “paperwork phase” can take as much emotional energy as the medical phase. It can help
to ask your neuromuscular clinic if they have a dedicated care coordinator or social worker for gene therapy
navigationsomeone who knows the exact dance steps insurance companies like to see.

What’s next in Duchenne gene therapy: the pipeline is busy

ELEVIDYS may be the first approved option, but it’s not the last word. Companies and academic groups are working on
next-generation approaches designed to improve muscle targeting, reduce liver risk, and expand eligibility.
Here are a few themes you’ll see in current research and development:

Next-gen AAV capsids and liver “detargeting” strategies

New candidates aim to deliver micro-dystrophin more efficiently to skeletal and cardiac muscle while reducing
exposure to the liverbecause fewer liver complications would be a very welcome plot twist. For example, investigational
programs like Solid Biosciences’ SGT-003 have emphasized capsid design goals that increase muscle targeting and
detarget the liver.

RGX-202 and other micro-dystrophin programs

REGENXBIO’s RGX-202 is another investigational Duchenne gene therapy designed around micro-dystrophin delivery, and
the company has reported ongoing clinical development milestones and interim updates. These programs are part of a
broader push to refine dosing, improve expression, and better understand functional outcomes.

Lessons learned from discontinued programs

Not every gene therapy program makes it to the finish line. Pfizer, for instance, announced it would discontinue
its investigational Duchenne gene therapy program after a Phase 3 study did not meet its primary endpoint. That’s
disappointingbut it’s also how medical science works in real life: the field learns, iterates, and (ideally) builds
safer and more effective options over time.

Questions to ask your neuromuscular team

If you’re discussing Duchenne gene therapy with your care team, these questions can help you move from “internet
overwhelm” to “informed plan”:

• Based on the current label, is my child eligible right now?
• What testing is needed (genetic confirmation, antibody testing, baseline labs, cardiac evaluation)?
• What is the corticosteroid plan before and after infusion?
• Where will monitoring happen, and how often will we need labs in the first 3 months?
• What symptoms should trigger an urgent call (jaundice, vomiting steroid doses, confusion, severe fatigue)?
• How might gene therapy affect the rest of the care plan (PT, cardiac meds, pulmonary follow-up)?
• What does insurance authorization typically look like at this center?

Pro tip: bring a notebook (or the notes app you trust with your life). The appointment will feel like drinking from
a firehose, and you deserve a written record.

Experiences families often share (and what they wish they’d known sooner)

No two Duchenne gene therapy journeys look exactly alike, but families and patients often describe a handful of
shared “chapters” that can help you set expectations. First comes the research spiral: you start
with one question“Is gene therapy an option?”and suddenly it’s 2:00 a.m., you’ve read three FDA updates, and you
have twelve tabs open about liver enzymes. (If that’s you, congratulations: you’re officially doing Duchenne parent
continuing education.)

Next is the eligibility phase, which can feel weirdly like applying to college, except the essay
prompt is “Please provide all labs since the beginning of time.” Genetic confirmation, antibody testing, baseline
liver labs, cardiac checkseach step is important, but it can be emotionally exhausting because it turns “hope” into
a sequence of pass/fail gates.

Families often say infusion day itself is both anticlimactic and intense. Anticlimactic because it’s an IV infusion
in a hospital room, not a movie montage with inspirational music. Intense because everyone in the room knows what’s
at stake. Many people describe the care team as calm and protocol-driven, which is exactly what you want. You’ll
likely hear the phrase “we’re going to monitor you closely” so many times it becomes background music.

Then comes the monitoring stretch, which is where real life kicks in: weekly lab visits, steroid
schedules, watching for symptoms, and trying to keep a child’s routine stable while your calendar looks like it was
attacked by a highlighter. Families often mention learning a new vocabularyALT, AST, bilirubin, troponinwords they
never wanted to know but now can pronounce confidently at the lab desk.

Emotionally, this phase can be complicated. Some families report feeling relief (“We did it. The infusion is done.”)
mixed with anxiety (“Now we wait and watch.”). Others describe a sense of whiplash: the outside world assumes gene
therapy means everything is fixed, while you’re still juggling therapies, appointments, and the everyday realities
of Duchenne. Many families say they wished friends and extended family understood one key point:
gene therapy can be meaningful without being a cure.

On the positive side, families often share that having a knowledgeable neuromuscular team and a clear monitoring
plan helps a lot. Practical tips people mention again and again include: keep a dedicated folder (digital or paper)
for lab results and insurance correspondence, set medication reminders that are impossible to ignore, and don’t be
shy about asking your clinic who to call after hours. Also: snacks. Always snacks. Hospitals run on paperwork, but
children run on snacks.

Finally, many families describe a shift in how they define “success.” Instead of expecting a dramatic overnight
change, they look for steadier, quieter wins: maintaining stamina, keeping up with peers a little longer, fewer
functional losses over time, or simply feeling they used every available tool responsibly. In that sense, the
“experience” of Duchenne gene therapy is often a mix of science, vigilance, and hopeplus a very human commitment to
giving a child the best shot at more good days.

Conclusion

Duchenne muscular dystrophy gene therapy is one of the most important advances the Duchenne community has seen in
decades. In the U.S., ELEVIDYS opened the door to systemic micro-dystrophin gene deliverywhile also reminding us
that powerful therapies require serious safety guardrails. The most up-to-date reality (as of late 2025) is that
eligibility is narrower than it briefly was, monitoring is more intensive, and clinics are treating gene therapy as
a high-stakes intervention that demands careful selection and follow-up.

The hopeful part is that the field is moving fast. New candidates aim to improve targeting, reduce liver risk, and
strengthen evidence for long-term benefit. If you’re navigating these decisions, the best next step is rarely “read
one more forum thread.” It’s a structured conversation with a neuromuscular team that knows your child’s history,
understands the current label, and can map out a plan that puts safety first.